La Jolla, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)California Institute for BioMedical Research, founded in 2011, is a mid-sized nonprofit that reported $98.8M in total revenue in fiscal year 2017. Revenue surged 2314% from the prior year, signaling strong growth momentum. The organization ran a surplus of $58.4M, a strong 59% operating margin.
Our mission is to build a unique institute that bridges basic research and drug discovery, and that attracts the best and brightest scientists, physicians and students to work together synergistically to find cures for neglected human diseases. The California Institute for Biomedical Research (CALIBR) is a biomedical research organization located in San Diego, California. CALIBR bridges the gap between basic biomedical research and the clinical application of research discoveries to human disease. CALIBR commits substantially all of its resources to biomedical research activities. CALIBR's research and work will catalyze the translation of discoveries by scientists at other San Diego research institutes, as well as other major research institutes throughout the world, into potential new therapies for many life threatening and debilitating diseases. These diseases include orphan diseases, degenerative diseases of aging, cancer, autoimmune diseases, and infectious diseases.
Research grants and contracts are received from public and private institutions and are used to conduct biomedical research. In the current fiscal year, CALIBR conducted research through a private...
Research grants and contracts are received from public and private institutions and are used to conduct biomedical research. In the current fiscal year, CALIBR conducted research through a private collaboration agreement on autoimmune and inflammatory diseases, cancer biology, cardiovascular metabolic diseases and neurobiology. In addition, it conducted research for the treatment of spinal muscular atrophy, juvenile diabetes, tb drug development, osteoarthritis, cryptosporidiosis and malaria.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2017 | 2016 | Change | |
|---|---|---|---|
| Revenue | $98,797,059 | $4,092,975 | +23.1% |
| Expenses | $40,377,736 | $4,353,309 | +8.3% |
| Net Income | $58,419,323 | $-260,334 | -225.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Peter G Schultz | CEO/President & Chair | 40.00 |
Officer
Director
|
$285,562 | $67,321 | $721,397 |
| Herbert Boyer | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Ronald Burkle | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Gerald Chan Start 32918 | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| John D Diekman Start 32918 | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Mark Edwards | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Peter C Farrell PHD DSc | Board Member (Start 3/28/18) | 1.00 |
Director
|
$0 | $0 | $0 |
| Isy Goldwasser | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Benedict Gross Start 92818 | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| William R Hearst III | Board Member (Start 3/29/18) | 1.00 |
Director
|
$0 | $0 | $0 |
| Jeffery Kelly Start 92818 | Board Member | 1.00 |
Director
|
$0 | $66,417 | $439,110 |
| Sherry Lansing Start 5718 | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Ge Li Start 32918 | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Claudia S Luttrell | Board Member (Start 3/29/18) | 1.00 |
Director
|
$0 | $0 | $0 |
| Joel S Marcus Start 32918 | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| John Martin Start 5718 | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Mark Pearson Start 32818 | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Bernard Saint-Donat PHD | Board Member (Start 3/28/18) | 1.00 |
Director
|
$0 | $0 | $0 |
| Paul R Schimmel End 92818 | Board Member | 1.00 |
Director
|
$0 | $21,185 | $65,485 |
| Christopher T Walsh | Board Member | 1.00 |
Director
|
$0 | $0 | $0 |
| Douglas A Bingham | Secretary/EVP of Scripps Florida | 1.00 |
Officer
|
$0 | $60,656 | $362,444 |
| Kelly San George End 32818 | CFO, CALIBR/Treasurer | 40.00 |
Officer
|
$67,786 | $1,443 | $69,229 |
| Jared M Machado | CFO,Scripps/Treasurer | 1.00 |
Officer
|
$0 | $65,619 | $339,049 |
| Matthew S Tremblay | COO,CALIBR/Secretary (End 3/28/18) | 40.00 |
Officer
|
$216,426 | $7,823 | $389,305 |
| Tamara L Barnas | Asst Secretary | 0.00 |
Officer
|
$0 | $23,393 | $114,737 |
| Leonardo Sahelijo | VP, Translational Medicine | 40.00 |
Highest
|
$365,208 | $22,775 | $387,983 |
| Vadim Klyushnichenko | VP of Pharm. Dev & Quality | 40.00 |
Highest
|
$314,321 | $28,151 | $342,472 |
| Arnab K Chatterjee | VP, Medicinal Chemistry | 40.00 |
Highest
|
$234,592 | $2,478 | $237,070 |
| Jing Li | VP, Program Management | 40.00 |
Highest
|
$216,149 | $5,431 | $221,580 |
| John A Wisler | VP, Toxicology and Pharmacokinetics | 40.00 |
Highest
|
$225,104 | $20,765 | $245,869 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2018 | $98,797,059 | $40,377,736 | No data | $58,419,323 |
Compare California Institute for BioMedical Research with other nonprofits in California and across the country.